½ÃÀ庸°í¼­
»óǰÄÚµå
1322954

¼¼°èÀÇ Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú ¹ßÀü°ú ¼ºÀå ±âȸ

Global Epifluidic Diagnostics Technology Advancements and Growth Opportunities

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 58 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯¿¬ÇÑ ¸¶ÀÌÅ©·Î À¯Ã¼ ¹× ÀüÀÚ°øÇÐÀÇ ÆÄ±«Àû ±â¼ú·Î Â÷¼¼´ë µð¹ÙÀ̽º °³¹ßÀ» ÃËÁø

ÀÌ Á¶»ç ¼­ºñ½º´Â Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼úÀÇ ¹ßÀüÀ» Á¶»çÇϰí, ÇコÄÉ¾î »ê¾÷¿¡ °¡Á®¿Ã ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´ÜÀº ÇǺο¡ ¹ÐÂøµÈ ¸¶ÀÌÅ©·Î À¯Ã¼ ½Ã½ºÅÛÀ» ÅëÇØ ¶¡°ú °£Áú¾×(ISF)À» ºÐ¼®ÇÒ ¼ö ÀÖ´Â »õ·Î¿î Á¾·ùÀÇ ¿þ¾î·¯ºí Áø´Ü ±â¼úÀÔ´Ï´Ù. ¸¶ÀÌÅ©·Î ÀÏ·ºÆ®·Î´Ð½º, ¼¾¼­ ¹× À¯¿¬ÇÑ ¸¶ÀÌÅ©·Î À¯Ã¼°øÇÐÀ» žÀçÇÑ ÀÌ ¼ÒÇüÀÇ À¯¿¬ÇÑ ÇǺΠºÎÂøÇü ÀåÄ¡´Â Á¤È®ÇÑ °Ç°­ °ü¸®¸¦ À§ÇØ Àå±â°£¿¡ °ÉÃÄ ÅëÁõ ¾øÀÌ Áö¼ÓÀûÀ¸·Î ´ëü »ýü À¯Ã¼¸¦ »ùÇøµÇϰí, Áø´Ü ´ë»óÀ» ½Ç½Ã°£À¸·Î Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ±â¼ú ¹ßÀü, ƯÈ÷ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML) ¼Ö·ç¼ÇÀÇ ÅëÇÕÀº ´õ ³ôÀº Áø´Ü Á¤È®µµ¿Í »ç¿ëÀÚ ÆíÀǼº Çâ»ó¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¿¬±¸ÁøÀº ¶¡°ú ISF ±â¹Ý Áø´ÜÀÌ ¹ÙÀÌ·¯½º °¨¿° °¨Áö, ³¶Æ÷¼º ¼¶À¯Áõ Áø´Ü, ¿ì·¹¾Æ ¸ð´ÏÅ͸µ, ÆÄŲ½¼º´ °ü¸® µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÉ ¼ö ÀÖ´Ù´Â Áõ°Å¸¦ ¹ß°ßÇß½À´Ï´Ù. ¶¡À» ±â¹ÝÀ¸·Î ÇÑ Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼úÀº ÁÖ·Î ¼öºÐ °ø±Þ °ü¸® ¹× ¹°Áú »ç¿ë °¨Áö¿¡ »ç¿ëµÇ¸ç, ISF¸¦ ±â¹ÝÀ¸·Î ÇÑ Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼úÀº ´ë»ç »ê¹° ÃøÁ¤¿¡ äÅõǰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ISF ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´ÜÀ» Ä¡·áÁ¦ ¸ð´ÏÅ͸µ, ½ÉÇ÷°ü Áúȯ ¸ð´ÏÅ͸µ, ÆÐÇ÷Áõ °¨Áö µî ´õ ¸¹Àº ÀÓ»ó ÀÀ¿ë ºÐ¾ß·Î Àû±ØÀûÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿©·¯ ºÐ¾ß¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´ÜÀº ÇâÈÄ ¸î ³â µ¿¾È ³ôÀº ½ÃÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ´Ù¾çÇÑ À¯ÇüÀÇ Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú°ú ±× ÀÌÁ¡À» Æ÷°ýÀûÀ¸·Î ´Ù·ç°í ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ» ÆÄ¾ÇÇÕ´Ï´Ù. ¶ÇÇÑ ¶¡ ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü°ú ISF ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´ÜÀÇ ÁÖ¿ä ÁøÀÔÀÚ¸¦ ½Äº°Çϰí, äÅÃµÈ ±â¼ú, Àû¿ë ºÐ¾ß, »ó¾÷Àû Áغñ ¼öÁØÀ» È®ÀÎÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ÀÚ±Ý Á¶´Þ, M&A, ƯÇã Ãâ¿ø µî Áö¿ª ¹× »ê¾÷ µ¿Çâµµ ´Ù·ç°í ÀÖ½À´Ï´Ù. ±âÁØ ¿¬µµ´Â 2022³â, ¿¹Ãø ±â°£Àº 2023-2027³âÀÔ´Ï´Ù.

¸ñÂ÷

Àü·«Àû °úÁ¦

  • ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö°í Àִ°¡? The Strategic Imperative 8(TM) : ¼ºÀåÀ» ¸·´Â ¿äÀÎ
  • The Strategic Imperative 8(TM)
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ¾÷°èÀÇ Å¾ 3 Àü·«Àû Áß¿ä »çÇ×ÀÇ ¿µÇâ
  • Growth Pipeline Engine(TM)
  • Á¶»ç ¹æ¹ý

¼ºÀå ±âȸ ºÐ¼®

  • ±âÁ¸ Áø´Ü¹ý°ú Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¹ý : ºñ±³
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â±âÀÇ ±¸¼º¿ä¼Ò¿Í »õ·Î¿î Çõ½Å
  • ¼¼ºÐÈ­
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ºÐ¼® ¹üÀ§

±â¼ú ºÐ¼® : ¶¡ ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú

  • °³¿ä
  • °æÀï ȯ°æ
  • Çмú Çõ½Å »ýŰ迡¼­ÀÇ »õ·Î¿î ¶¡ °¨Áö ¾ÖÇø®ÄÉÀ̼Ç

±â¼ú ºÐ¼® : ISF ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¾à

  • °³¿ä
  • °æÀï ȯ°æ
  • Çаè Çõ½Å »ýŰ迡¼­ÀÇ »õ·Î¿î ISF ¼¾½Ì ¾ÖÇø®ÄÉÀ̼Ç

Çõ½Å ÁöÇ¥

  • ´Ù¸¥ Ç¥Àû ºÐ¼®¹°¿¡ ´ëÇÑ ¶¡ ¹× ISF ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¾àÀÇ »ó¾÷Àû ÀÌ¿ë °¡´É¼º
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¾à : ´Ù¾çÇÑ ¾ÖÇø®ÄÉÀ̼ǰú °³¹ß »óȲ
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¾à ±â¼ú ·Îµå¸Ê
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â±â °³¹ßÀÇ Áö¿ª µ¿Çâ
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â±â »ê¾÷ÀÇ M&A ºÐ¼®(2020-2023³â)
  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý ºÐ¼®(2020-2023³â)
  • 2020-2023³â, Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¹Î°£ ÀÚ±Ý Á¶´Þ ÇöȲ

ƯÇ㠺м®

  • Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü¾à¿¡ °üÇÑ ÁöÀûÀç»ê Ȱµ¿ ºÐ¼®(2018-2023³â)
  • ¶¡ ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú - Çõ½Å Å׸¶ ºÐ¼®(2018-2023³â)
  • ISF ±â¹Ý Ç¥ÇÇ ¸¶ÀÌÅ©·Î À¯Ã¼ Áø´Ü ±â¼ú - Çõ½Å Å׸¶ ºÐ¼®(2018-2023³â)

¼ºÀå ±âȸ À¯´Ï¹ö½º

  • ¼ºÀå ±âȸ 1 : ´ëü »ùÇà °¡´ÉÇÑ ¹ÙÀÌ¿À À¯Ã¼¸¦ ºÐ¼®ÇÏ´Â ½Å±Ô ¸¶ÀÌÅ©·Î À¯Ã¼ ½Ã½ºÅÛ
  • ¼ºÀå ±âȸ 2 : IoT, AI/ML ¾Ë°í¸®Áò, ±âŸ ÷´Ü Á¤º¸Åë½Å±â¼ú
  • ¼ºÀå ±âȸ 3 : ÁÖ¿ä ±â¾÷, Çмú±â°ü, Á¤ºÎ°£ Çù¾÷

ºÎ·Ï

  • ±â¼ú ¼º¼÷µµ ·¹º§(TRL) : ¼³¸í
  • ƯÇã

´ÙÀ½ ½ºÅÜ

  • ´ÙÀ½ ½ºÅÜ
  • ¿Ö FrostÀΰ¡, ¿Ö Áö±ÝÀΰ¡?
  • ¸éÃ¥»çÇ×
ksm 23.08.22

Disruptive technologies in flexible microfluidics and electronics are driving the development of next-generation devices

This research service examines the advancements in epifluidic diagnostics technology, identifying the growth opportunities they present for the healthcare industry. Epifluidic diagnostics is an emerging class of wearable diagnostics that enables sweat and interstitial fluid (ISF) analysis through skin-interfaced microfluidic systems. These body-worn skin-conformable and flexible miniature devices with microelectronics, sensors, and flexible microfluidics allow long-term, painless, and continuous sampling of the alternate biofluids and real-time and continuous monitoring of diagnostic targets for precise health management. Technology advancements in this field, particularly the integration of artificial intelligence (AI) and machine learning (ML) solutions, help enable higher diagnostics accuracy and enhanced user convenience.

Researchers have found evidence that sweat- and ISF-based diagnostics can be used for a diverse range of applications, including viral infection detection, cystic fibrosis diagnosis, urea monitoring, and Parkinson's disease management. Sweat-based epifluidic diagnostics are predominantly utilized for hydration management and substance-use detection, while ISF-based epifluidic diagnostics are employed for metabolite measurement. Key players are actively expanding ISF-based epifluidic diagnostics for more clinical uses, such as therapeutic drug monitoring, cardiovascular disease monitoring, and sepsis detection. With several sectors of impact, epifluidic diagnostics has high market potential in the coming years.

The report takes a comprehensive look at the different types of epifluidic diagnostic technologies and their benefits and identifies the factors driving and restraining the growth of this market. It also identifies the key participants in the sweat-based epifluidic diagnostics and ISF-based epifluidic diagnostics segments, examining the technologies they employ, their target applications, and commercial readiness levels. The study covers regional and industry trends, including funding rounds, mergers and acquisitions (M&A), and patents filed. The base year is 2022, and the forecast period is 2023 to 2027.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Epifluidic Diagnostics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • Conventional Diagnostics and Epifluidic Diagnostics: A Comparison
  • Components of an Epifluidic Diagnostic Device and Emerging Innovations
  • Segmentation
  • Growth Drivers
  • Growth Restraints
  • Scope of Analysis

Technology Analysis: Sweat-based Epifluidic Diagnostics

  • Overview
  • Competitive Environment
  • Emerging Sweat-sensing Applications from the Academic Innovation Ecosystem

Technology Analysis: ISF-based Epifluidic Diagnostics

  • Overview
  • Competitive Environment
  • Emerging ISF-sensing Applications from the Academic Innovation Ecosystem

Innovation Indicators

  • Commercial Availability of Sweat- and ISF-based Epifluidic Diagnostics for Different Target Analytes
  • Epifluidic Diagnostics: Diverse Applications and Development Status
  • Technology Roadmap of Epifluidic Diagnostics
  • Regional Trends of Epifluidic Diagnostic Device Development
  • Analysis of M&As in the Epifluidic Diagnostics Industry, 2020-2023
  • Analysis of Government Funding for Epifluidic Diagnostics, 2020-2023
  • Snapshot of Private Funding for Epifluidic Diagnostics, 2020-2023

Patent Analysis

  • IP Activity Analysis on Epifluidic Diagnostics (2018-2023)
  • Sweat-based Epifluidic Diagnostics-Innovation Themes Analysis (2018-2023)
  • ISF-based Epifluidic Diagnostics-Innovation Themes Analysis (2018-2023)

Growth Opportunity Universe

  • Growth Opportunity 1: Novel Microfluidic Systems Analyzing Alternate Sampleable Biofluids
  • Growth Opportunity 2: IoT, AI/ML Algorithms, and Other Advanced Information and Communication Technologies
  • Growth Opportunity 3: Collaborations between Key Players, Academic Institutes, and Governments

Appendix

  • Technology Readiness Levels (TRL): Explanation
  • Patents

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦